Thrombos is in veins and arteries are treated with the help of anticoagulants. They can be given either by parenteral or oral route. Before we use to have only vitamin K antagonists (VKAs), such as warfarin and Acitrom which are very useful and effective but have lots of limitations, which complicate its management. This led to discovery of newer oral anticoagulants (NOACs) which were more patient friendly. These agents inhibit thrombin and factor Xa. As vitamin K intake has no effect on the activity of the NOACs, these drugs produced a more predictable anticoagulant response than vitamin K antagonists. They also had less drug-drug interactions. These drugs have totally changed the way we treat the patients suffering from thrombosis.
- 10.Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Peter S, John Camm A, Kirchhof P. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefGoogle Scholar
- 13.Masotti L, Pampanini M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. Ital J Med. 2013;7(8S):1–7. https://doi.org/10.4081/itjm.s8.1.
- 15.Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefGoogle Scholar